Skip to content
Clinical Trials – home

Neisseria catarrhalis: a bacterial component of Ismigen, studied in respiratory infections

1 / 1
trials open to patients / all trials
1+
Countries

In short

Neisseria catarrhalis is a bacterium included as one of eight bacterial components in Ismigen, a sublingual tablet authorised as a medicine in Poland. Ismigen is being studied in a Phase 3 trial to see whether it can reduce the number of respiratory tract infections in children aged 3 to 12 years. The trial plans to enrol 224 children and is currently authorised.

Key points

  • Neisseria catarrhalis is one of eight bacterial components in the authorised medicine Ismigen.
  • Ismigen is given as a sublingual tablet (50 mg) that dissolves under the tongue.
  • The ongoing trial is Phase 3 and plans to enrol 224 children aged 3 to 12 years.
  • The trial compares Ismigen with a placebo over a 3-month treatment period and 4-month follow-up.
  • The main measure is the number of respiratory tract infections each child experiences.

What is neisseria catarrhalis?

Neisseria catarrhalis is a bacterium that forms part of a fixed combination of eight bacterial components in the medicine Ismigen (also known as PMBL). The product record lists the full combination as Haemophilus influenzae, Klebsiella ozaenae, Klebsiella pneumoniae, neisseria catarrhalis, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes and Streptococcus viridans. Ismigen is authorised as a medicine in Poland, where it is marketed as Ismigen tabletki podjęzykowe by Lallemand Pharma Europe.

In the registered trial, this substance combination is the tested product rather than a comparison arm. The product is classified within the therapeutic area of respiratory tract diseases.

How does neisseria catarrhalis work?

The medicine containing neisseria catarrhalis is a polyvalent mechanical bacterial lysate (PMBL). Bacterial lysates are prepared from inactivated bacteria and are intended to stimulate the body's immune defences. The trial record describes the product as a sublingual tablet used according to the Summary of Product Characteristics (SmPC) instructions during the autumn and winter period. The registry data provided does not include a detailed molecular mechanism of action for the individual bacterial components.

Which conditions is it used or studied for?

  • Respiratory tract infections (RTIs) — the authorised medicine is being studied to see whether it reduces the number of respiratory infections in children during the autumn and winter season.

How is neisseria catarrhalis given?

The product containing neisseria catarrhalis is a sublingual tablet with a strength of 50 mg, given by sublingual use (placed under the tongue to dissolve). The trial also includes a placebo arm given in the same sublingual form.

What do the clinical trials show?

One clinical trial is registered for this substance combination. It is a Phase 3, interventional study that plans to enrol 224 children aged 3 to 12 years with respiratory tract infections. The trial is currently authorised, meaning it has received approval to proceed.

The primary outcome is the rate of respiratory tract infections, measured as the number of RTIs each child experiences over a 3-month treatment period plus a 4-month follow-up period, a total observation window of 7 months. The trial compares the sublingual tablet with a placebo. Results are not yet reported in the registry record.

Questions people often ask

Conditions where Neisseria catarrhalis is being studied

Each condition opens its own overview and trial list

Trials with Neisseria catarrhalis

Recruiting trials first

See all 1 →
Quick filters
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.